Institute of Animal Pathology, Vetsuisse Faculty, Länggassstrasse, University of Bern, 3012, Bern, Switzerland.
Division of Molecular Pathology, The Netherlands Cancer Institute, 1006 BE, Amsterdam, The Netherlands.
Genome Med. 2018 Dec 28;10(1):101. doi: 10.1186/s13073-018-0612-8.
Inhibitors of poly(ADP-ribose) polymerase (PARPi) have entered the clinic for the treatment of patients with cancers that lack homology-directed DNA repair, but drug resistance remains a clinical hurdle. Recent advances in the identification of PARPi resistance mechanisms have yielded a better understanding of DNA end protection and the relevance of endogenous poly(ADP-ribose) glycohydrolase, highlighting new vulnerabilities.
聚（ADP-核糖）聚合酶（PARPi）抑制剂已进入临床，用于治疗缺乏同源定向 DNA 修复的癌症患者，但耐药性仍然是临床面临的一个难题。最近在鉴定 PARPi 耐药机制方面的进展，使人们更好地理解了 DNA 末端保护和内源性聚（ADP-核糖）糖水解酶的相关性，突出了新的弱点。
